FDA’s Real-Time Adverse Event Reporting Dashboard for Cosmetics: A New Era of Transparency
Published: September 2025 Imagine you bought a new shampoo, hair dye, or moisturizer. A few days later, you notice a rash, excessive itching, or even worse. What would you do? Report it—but often, you might wonder whether your report ever makes a difference. With the FDA’s launch of its new dashboard for real-time adverse event […]
Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry
Understanding the Guidance: What, Why, How In September 2025, the U.S. Food and Drug Administration (FDA) issued a nonbinding guidance for industry titled “Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations.” U.S. Food and Drug Administration This document gives detailed recommendations for sponsors developing therapeutic protein biosimilars, especially how to design […]
FDA’s Guidance on Alternative Tools for Assessing Drug Manufacturing Facilities: What It Means for Pharma
In September 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance document titled “Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications.” This guidance redefines how regulators and industry navigate facility assessments for pending drug applications—including NDAs, ANDAs, and BLAs. The new framework signals FDA’s intent to use more flexible, risk-based […]
RYBREVANT (amivantamab-vmjw) 2025 Label: What Changed, Why It Matters, and How to Apply It in Practice
Bottom line: In early 2025 the RYBREVANT label tightened safety language (notably infusion-related reactions, anaphylaxis placement, and venous thromboembolism management with lazertinib) and clarified dosing/administration details. Later in 2025, FDA accepted a supplement to update overall survival results from MARIPOSA, which will flow into Clinical Studies once the updated PI posts. Together, these moves round […]
FDA Issues Class I Recall for Boston Scientific Carotid Stent
What Happened: Scope & Rationale On August 22, 2025, the FDA classified as Class I the recall of Boston Scientific’s Carotid WALLSTENT Monorail Endoprosthesis, a self-expanding stent used to treat carotid artery narrowing U.S. Food and Drug AdministrationCardiovascular Business. Affected models (over 26,000 globally, including 1,333 in the U.S.) were found to have a manufacturing […]
FDA Issues Import Alerts on Olympus Medical Devices Made in Japan
Background & Regulatory Action On June 24, 2025, the U.S. Food and Drug Administration (FDA) issued Import Alert 89-04, targeting certain Olympus medical devices manufactured at its Aizu facility in Fukushima, Japan. These include: The alert effectively blocks 58 specific models from entering the U.S., citing ongoing violations of Quality System regulations (QSR) despite Olympus’ […]
Blog: FDA Urges Strict Adherence to Safe Use of Hyperbaric Oxygen Therapy Devices
1. Context & Safety Warning On August 25, 2025, the FDA issued a Letter to Health Care Providers, reminding clinicians and facilities of the critical importance of following manufacturer instructions when using hyperbaric oxygen therapy (HBOT) devices—given rising reports of serious injuries and fatalities U.S. Food and Drug Administration. Key recommendations include: The FDA emphasized […]
FDA Safety Labeling Changes for ACTEMRA (tocilizumab): What Changed, PV & Regulatory Impact, and a Playbook for Shudarsana
What changed in the U.S. label Newest update (August 8, 2025): Recent prior update (September 2024): Practical takeaway: Two concurrent risk domains now shape operations—expanded pediatric COVID-19 use (dosing, handling, benefit–risk) and heightened vigilance for severe hypersensitivity/SCARs. FDA Access Data+1 What needs to change internally (manufacturer/MAH “to-do” list) Pharmacovigilance impact Signal detection & case processing […]
FDA warns against unapproved epinephrine nasal solutions from BPI Labs & Endo USA: what happened, why it matters, and what to do now
Key takeaways What the FDA alert actually says On Jan 16, 2025, the FDA told health care professionals not to use unapproved epinephrine nasal solutions from BPI Labs and Endo USA because they’re being mistaken for injectable epinephrine. The agency emphasized that the nasal products are not sterile, so any IV administration could cause infection […]